睿知中国疾病研究地图
候选清单0

正在招募神经母细胞瘤I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.

ClinicalTrials.gov 上登记的一项神经母细胞瘤开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 2

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
  2. 研究中心东莞台心医院Dongguan Taixin Hospital东莞医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06836505,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 1 岁 至 50 岁;性别:不限

    登记记录的入选字段

  2. Patients who have received radiation therapy within 2 weeks prior to infusion;

    排除标准第 3 条

  3. Karnofsky performance status (for patients ≥16 years) or Lansky performance status (for patients <16 years) (Appendix 1) must be at least 50;

    入选标准第 5 条

  4. Renal function: Plasma creatinine ≤ 1.5 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m²;

    入选标准第 8 条

  5. Patients with active hepatitis B (defined as HBV DNA > 500 IU/mL) or hepatitis C (HCV RNA positive);

    排除标准第 4 条

    HIV-positive patients or patients with a positive syphilis test;

    排除标准第 5 条

    Primary malignant tumors that have been completely resected and have been in complete remission for ≥5 years;

    排除标准第 11 条

  6. Patients of childbearing potential (both male and female) must agree to use reliable contraception methods (hormonal or barrier methods or abstinence) with their partner until at least 12 months after CAR-T cell infusion, and until two consecutive flow cytometry or PCR tests show no CAR-T cells in the body;

    入选标准第 12 条

    Pregnant or breastfeeding female patients;

    排除标准第 12 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06836505,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patients who are diagnosed as relapsed/refractory neuroblastoma or relapsed/refractory desmoplastic small round cell tumors;
  2. Age 1-50 years, any gender;
  3. Agree to participate in the trial and sign a written informed consent form;
  4. Expected survival of ≥12 weeks;
  5. Karnofsky performance status (for patients ≥16 years) or Lansky performance status (for patients <16 years) (Appendix 1) must be at least 50;
  6. Good function of major organs:
  7. Liver function: ALT ≤ 5 times the upper limit of normal for the corresponding age, and bilirubin ≤ 2.0 mg/dL, except for patients with Gilbert-Meulengracht syndrome. Patients with Gilbert-Meulengracht syndrome who have bilirubin ≤ 3.0 times the upper limit of normal and direct bilirubin ≤ 1.5 times the upper limit of normal may be included;
  8. Renal function: Plasma creatinine ≤ 1.5 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m²;
  9. Pulmonary function: Oxygen saturation ≥ 95% in room air;
  10. Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 45%;
  11. Patients using the following medications must meet the following conditions:
  12. Patients of childbearing potential (both male and female) must agree to use reliable contraception methods (hormonal or barrier methods or abstinence) with their partner until at least 12 months after CAR-T cell infusion, and until two consecutive flow cytometry or PCR tests show no CAR-T cells in the body;
  13. If the subject cannot provide suitable T cells for CAR-T preparation, T cells from a healthy donor may be collected for preparation.

排除标准:Exclusion Criteria:

  1. Patients with any of the following items will not be enrolled in this study:
  2. Patients with increased intracranial pressure or altered consciousness;
  3. Patients who have received radiation therapy within 2 weeks prior to infusion;
  4. Patients with active hepatitis B (defined as HBV DNA > 500 IU/mL) or hepatitis C (HCV RNA positive);
  5. HIV-positive patients or patients with a positive syphilis test;
  6. Patients with uncontrolled acute life-threatening bacterial, viral, or fungal infections (e.g., positive blood cultures within ≤72 hours before infusion);
  7. Patients with unstable angina and/or myocardial infarction within 6 months prior to screening;
  8. Patients with a history of or concurrent malignancies, except for the following conditions:
  9. Basal cell carcinoma or squamous cell carcinoma that has been adequately treated (sufficient wound healing required before study enrollment);
  10. Carcinoma in situ of the cervix or breast that has been cured, with no signs of recurrence for at least 3 years before the study;
  11. Primary malignant tumors that have been completely resected and have been in complete remission for ≥5 years;
  12. Pregnant or breastfeeding female patients;
  13. Patients with uncontrolled arrhythmias that have not been managed medically;
  14. Patients who need oral anticoagulation therapy within 1 week before CAR-T cell infusion;
  15. Patients with active neuroautoimmune or inflammatory diseases (e.g., Guillain-Barré syndrome, amyotrophic lateral sclerosis);
  16. Other conditions deemed inappropriate for participation in the clinical study by the investigator.

引自 ClinicalTrials.gov, NCT06836505, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06836505,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06836505